Expression of PD-L 1 associated with Ki-67 and chemotherapy response but not p 53 in osteosarcoma

Zhengjie Yang,Guoxin Zhu,Xiao Yang,Ke Zeng,Fengxiang Liu,Junying Sun

2018-01-01

Abstract:Purpose: Osteosarcoma (OS) is highly aggressive and confers poor prognosis. Novel immune checkpoint inhibition holds promise for treatment yet the role of PD-L1 in OS remains undetermined. Methods: Paraffinized OS sections were collected and stained with immunohistochemistry (IHC) for PD-L1, Ki-67, and p53. Clinicopathological parameters of corresponding patients were gathered and analyzed statistically for association and correlation. PD-L1 positivity was evaluated using 1% and 5% cutoffs. Results: Ninety-two OS samples, excised between 1997 to 2017, were collected. Sixty-five samples were assessed as PD-L1 positive using 1% cutoff and 50 samples were positive using 5% cutoff. PD-L1 positivity (1%) was significantly associated with trunk location (P=.018), elevated serum lactate dehydrogenase (LDH) (P=.018), advanced clinical stage (P<.001), distant metastasis (P<.001), and poor response to chemotherapy (P<.001). PD-L1 positivity (1%) was not associated with age, gender, tumor size, or serum level of alkaline phosphatase. PD-L1 positivity (5%) was significantly associated with all significant parameters associated with 1% cutoff, with an additional association with larger tumor size (P=.022) and exception of elevated LDH (P=.017). Cutoff of 1% showed significant correlation with expression of Ki-67 (P<.001) and p53 (P=.024). Cutoff of 5%, however, was only correlated with expression of Ki-67 (P<.001). Conclusion: PD-L1 expression is positive in most OS and is associated with a more aggressive phenotype. PD-L1 expression is also associated with poor chemotherapy response and is correlated with Ki-67. The present results support the application of PD-L1 blockade in OS.